Compare Abbott Laboratories (ABT) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs ThredUp Inc — how do they compare? Abbott Laboratories trades at $112.05 (market cap $191.92B), while ThredUp Inc trades at $3.09 (market cap $405.82M). The key difference: Abbott Laboratories is far larger — about 472.9× ThredUp Inc's market cap, and Abbott Laboratories pays a 2.27% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| ABT | TDUP | |
|---|---|---|
Market Cap | $191.92B | $405.82M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $12.08 |
52-Week Low | $82.57 | $3.08 |
Enterprise Value | $218.92B | $404.00M |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.02% with strong analyst support (75.6% buy ratings) and a $120.70 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026. Fundamentals remain solid with $44.33B revenue, 11.65% net margin, and improving cash flow trends. Recent CE Mark approval for Libre Duo glucose-ketone sensors highlights innovation momentum.
ABT presents a compelling investment case with strong fundamentals, positive analyst sentiment, and innovative product pipeline. Key risks include competitive pressures in medical devices and potential macroeconomic headwinds affecting healthcare spending. The stock's current valuation at 35.15 P/E appears reasonable given growth prospects and dividend stability.
ThredUp (TDUP) trades at $3.08, down 4.64% amid a bearish technical signal. The company reported Q2 2026 revenue growth of 16.9% to $90.8 million but missed EPS estimates and cut full-year revenue guidance, triggering a sharp stock decline. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Analyst consensus is positive with 57% buy ratings, but recent news highlights shareholder investigations and promotional headwinds.
The outlook is clouded by near-term execution risks and persistent losses, though long-term potential exists if the company can leverage its asset-light model and AI tools to achieve profitability. Key risks include competitive pressures, macroeconomic sensitivity, and the need to improve cost management. Investors should weigh analyst optimism against the company's challenging path to sustained earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
